# Breakthrough Advances in Guillain-Barr� Syndrome Treatment Announcing the Efficacy of Tanruprubart at AAN 2025

# Breakthrough Advances in Guillain-Barr� Syndrome Treatment Announcing the Efficacy of Tanruprubart at AAN 2025

'Abstract:' This article summarises pivotal Phase 3 data presented by Annexon at the American Academy of Neurology's 2025 Annual Meeting, reinforcing the potential of Tanruprubart (formerly ANX005) as a targeted therapy for Guillain-Barr� Syndrome (GBS). Insights into the clinical benefits observed across all stages of GBS bolster the therapeutic landscape for this challenging condition. We also explore market sentiments surrounding Annexon amid…

Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barr Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting

April 08, 2025 16:05 ET  | Source: Annexon Biosciences Oral Presentation Features Phase 3 Data Showing Rapid Recovery and Durable Benefit of Tanruprubart (formerly ANX005) on Clinically Meaningful Measures across Multiple Stages of GBS Disease Education Campaign for Healthcare Providers called Move GBS Forward™ (MoveGBSForward.com) Highlights Life-altering Impact of GBS BRISBANE, Calif., April 08, 2025 […]